ClinicalTrials.gg
RecruitingNCT07206407Updated Dec 17, 2025

Clinical Trial on Rapid Immune Modulating Effects

An interventional study of Placebo and Nutraceutical blend in Immune Surveillance, sponsored by Natural Immune Systems Inc. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Natural Immune Systems Inc · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal for this clinical trial is to document rapid effects of a nutritional blend on immune cells. A double-blind, placebo-controlled, cross-over study design will be used.

Read the detailed description

Clinical trial comparing the acute immune effects of a nutraceutical blend, and a placebo. The nutraceutical blend is based on low molecular weight peptides isolated from cow colostrum ultrafiltrate, mushroom extracts, and vitamin C.

24 subjects will participate in a placebo-controlled, randomized, double-blinded, cross-over study design, wherein they will be consuming placebo or the active nutraceutical blend, separated by a 1-week washout period.

Baseline blood samples are taken 1 hour after participants arrive; the dose is then administered. Additional blood samples are taken 1 hour, 2 hours, and 3 hours following consumption of test product.

02

Conditions studied

  • Immune Surveillance
03

In context

Lead sponsor

Natural Immune Systems Inc is the lead sponsor of 25 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults;
  • Age 18-75 years (inclusive);
  • Veins easy to see in one or both arms (to allow for the multiple blood draws);
  • Willing to comply with study procedures, including:

    • Maintaining a consistent diet and lifestyle routine throughout the study,
    • Consistent habit of bland breakfasts on days of clinic visits,
    • Abstaining from exercising and nutritional supplements on the morning of a study visit,
    • Abstaining from use of coffee, tea, and soft drinks for at least one hour prior to a clinic visit;
    • Abstaining from music, candy, gum, computer/cell phone use, during clinic visits.

Exclusion criteria

Exclusion Criteria:

  • Previous major gastrointestinal surgery (absorption of test product may be altered) (minor surgery not a problem, including previous removal of appendix and gall bladder);
  • Taking anti-inflammatory medications on a daily basis;
  • Currently experiencing intense stressful events/ life changes;
  • Currently in intensive athletic training (such as marathon runners);
  • Currently taking antipsychotic medications such as clozapine, Risperdal, Abilify, Zyprexa or Seroquel;
  • An unusual sleep routine (examples: working graveyard shift, irregular routine with frequent late nights, studying, partying);
  • Unwilling to maintain a constant intake of supplements over the duration of the study;
  • Anxiety about having blood drawn;
  • Pregnant, nursing, or trying to become pregnant;
  • Known allergies related to ingredients in active test product or placebo.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Experimental: Crossover group 1, randomized

    Crossover study: Participants consume a test product on each of the two clinic visits, at least 1 week apart, allowing for 1 week wash-out period between each product. Participants will consume the active test product versus placebo over 2 weeks. The order of interventions for this group is A, B.

    Dietary Supplement: Placebo · Dietary Supplement: Nutraceutical blend

  • Experimental
    Experimental: Crossover group 2, randomized

    Crossover study: Participants consume a test product on each of the two clinic visits, at least 1 week apart, allowing for 1 week wash-out period between each product. Participants will consume the active test product versus placebo over 2 weeks. The order of interventions for this group is B, A.

    Dietary Supplement: Placebo · Dietary Supplement: Nutraceutical blend

Interventions

  • Dietary supplementPlacebo

    Four capsules.

  • Dietary supplementNutraceutical blend

    Four capsules.

06

What researchers measure

Primary outcomes

  1. Immune cell surveillance

    Observation of changes in immune cell trafficking, i.e., the changes in immune cell numbers in the peripheral blood following administration. Data is collected as 'cell numbers per uL whole blood' for the following immune cell types: * Monocytes * NK cells * NKT cells * T cells * non-NK nonT cells

    Time frame: 3 hours after consuming a test product for this study protocol

Secondary outcomes

  1. Immune cell activation status

    Observation of immune cell status of alertness, i.e., the changes in the expression of CD25 and CD69. Data is collected as 'mean fluorescence intensity' for the following immune cell types: * Monocytes * NK cells * NKT cells * T cells * nonNK nonT cells

    Time frame: 3 hours after consuming a test product for this study protocol

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Feb 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Oct 3, 2025
StartActual
Sep 28, 2025
Primary completionEst.
Feb 1, 2026
CompletionEst.
Mar 1, 2026
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07206407
Lead sponsor
Natural Immune Systems Inc
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Sep 28, 2025
Primary completion
Feb 1, 2026 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Dec 17, 2025

Study contacts

Gitte S. Jensen, PhD
Contact
gitte@nislabs.com
15418840112
Gitte S. Jensen, PhD
principal investigator · NIS Labs

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion